.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
Moodys
UBS
Fish and Richardson
Citi
US Army
McKesson
Farmers Insurance
Daiichi Sankyo

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204525

« Back to Dashboard

NDA 204525 describes FLUDEOXYGLUCOSE F18, which is a drug marketed by Downstate Clincl, 3d Imaging Drug, Biomedcl Res Fdn, Brigham Womens, Cardinal Health 414, Childrens Hosp Mi, Cpdc, Essential Isotopes, Feinstein, Global Isotopes Llc, Hot Shots Nm Llc, Houston Cyclotron, Jubilant Draximage, Kettering Medctr, Kreitchman Pet Ctr, Lantheus Medical, Ma General Hosp, Mcprf, Mem Sloan-kettering, Methodist Hosp Res, Midwest Medcl, Mips Crf, Ncm Usa Bronx Llc, Petnet, Precision Nuclear, Queen Hamamatsu Pet, Shertech Labs Llc, Spectron Mrc Llc, Trustees Univ Pa, Ucla Biomedical, Ucsf Rodiopharm, Uihc Pet Imaging, Univ Michigan, Univ North Dakota, Univ Tx Md Anderson, Univ Utah Cyclotron, Weill Medcl Coll, Wi Medcl Cyclotron, Wusm Cyclotron, and Zevacor Pharma Inc, and is included in forty-one NDAs. It is available from thirty-four suppliers. Additional details are available on the FLUDEOXYGLUCOSE F18 profile page.

The generic ingredient in FLUDEOXYGLUCOSE F18 is fludeoxyglucose f-18. There are eight drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the fludeoxyglucose f-18 profile page.

Summary for 204525

Tradename:1
Applicant:1
Ingredient:1
Patents:0

Pharmacology for NDA: 204525

Mechanism of ActionRadiopharmaceutical Activity

Suppliers and Packaging for NDA: 204525

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 204525 ANDA Centre for Probe Development and Commercialization 21731-647 21731-647-03 2.5 mL in 1 SYRINGE (21731-647-03)
FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 204525 ANDA Centre for Probe Development and Commercialization 21731-647 21731-647-10 10 mL in 1 VIAL (21731-647-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength20-300mCi/ML
Approval Date:Oct 29, 2014TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
QuintilesIMS
Daiichi Sankyo
Moodys
McKesson
Boehringer Ingelheim
Julphar
Fuji
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot